戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 (formerly YbfM) have increased resistance to duramycin.
2 ox status of the lung tissue whereas (99m)Tc-duramycin, a new marker of cell injury, senses cell deat
3                                              Duramycin, a peptide that binds phosphatidylethanolamine
4 s) mutant became extremely hypersensitive to duramycin, although the sensitivity to papuamide A was u
5 ven the unique physicochemical properties of duramycin and the availability of PtdE in acute cell dea
6 this study was to develop and evaluate 99mTc-duramycin as a novel molecular probe for imaging PtdE.
7  high-dose radiation exposure, using (99m)Tc-duramycin as a phosphatidylethanolamine-binding radiopha
8 e potential use of (99m)Tc-HMPAO and (99m)Tc-duramycin as redox and cell-death imaging biomarkers, re
9 on, followed by a gradual decline in (99m)Tc-duramycin binding accompanied by extensive thymic atroph
10                               Finally, 99mTc-duramycin binding to acute cell death in vivo was demons
11 motherapy and radiotherapy increased (99m)Tc-duramycin binding to COLO205 cells in a concentration/do
12                                              Duramycin binds phosphatidylethanolamine (PtdE) at a 1:1
13 enously with either (99m)Tc-HMPAO or (99m)Tc-duramycin (both 37-74 MBq), and planar images were acqui
14                 We demonstrated that (99m)Tc-duramycin can be used to image induction of cell death e
15                                      (99m)Tc-duramycin cell binding and the levels of cell death were
16  apoptosis was assessed using (99m)Tc-linear duramycin control radiotracer.
17                      Blocking with unlabeled duramycin demonstrated specific binding of the radiotrac
18 PE-specific cyclic peptide lantibiotic agent Duramycin efficiently inhibits the entry of West Nile, d
19 g toxins that target PS (papuamide A) or PE (duramycin) exposed in the extracellular leaflet.
20                   The specificity of (99m)Tc-duramycin for apoptosis was assessed using (99m)Tc-linea
21 , our aim was to validate the use of (99m)Tc-duramycin for imaging the early response of tumors to tr
22                 Intravenously injected 99mTc-duramycin has favorable pharmacokinetic and biodistribut
23                                      (99m)Tc-duramycin holds promise as a noninvasive imaging radiotr
24                 The specific uptake of 99mTc-duramycin in apoptotic cells, compared with that in viab
25                                      (99m)Tc-duramycin is a SPECT tracer for cell death imaging.
26                                        99mTc-duramycin is a stable, low-molecular-weight PtdE-binding
27                                        99mTc-duramycin is completely unmetabolized in vivo, and the i
28                                              Duramycin is covalently modified with succinimidyl 6-hyd
29                               Sensitivity to duramycin is restored by expression of B. subtilis PetA
30                     The inhibitory effect of Duramycin is specific: it inhibits TIM1-mediated, but no
31                    With only 19 amino acids, duramycin is the smallest known polypeptide that has a d
32                                      (99m)Tc-duramycin lung uptake was also maximal at 7 d of exposur
33                                  Analysis of duramycin-mediated killing upon induction of PE synthesi
34                    Planar whole-body (99m)Tc-duramycin scanning (n = 4 per time point) was conducted
35            We have demonstrated that (99m)Tc-duramycin specifically accumulates in apoptotic tumors i
36 onclusion: We have demonstrated that (99m)Tc-duramycin specifically accumulates in apoptotic tumors i
37    Therapy response was evaluated by (99m)Tc-duramycin SPECT 24 h after the last dose of therapy.
38  response evaluation was assessed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-s
39  response evaluation was assessed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-s
40        Here, using the antimicrobial peptide duramycin that targets outward-facing PE, we show that B
41 epatic background, the avid binding of 99mTc-duramycin to the infarcted myocardium quickly becomes co
42 tment, indicating specificity of the (99m)Tc-duramycin tumor signal.
43                  No change in (99m)Tc-linear duramycin uptake could be detected in COLO205 tumors aft
44                             In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3
45 After tumor irradiation with 4.5 Gy, (99m)Tc-duramycin uptake in tumors increased significantly (1.24
46 and 3 wk after receipt of 15 Gy, and (99m)Tc-Duramycin uptake was more than doubled at 2 and 3 wk.
47     Results: COLO205 tumor uptake of (99m)Tc-duramycin was increased 7-fold from baseline in conatumu
48              COLO205 tumor uptake of (99m)Tc-duramycin was increased 7-fold from baseline in conatumu
49         Finally, using fluorescently labeled duramycin we demonstrate that cells lacking PetA have re
50 armacokinetics, and biodistribution of 99mTc-duramycin were measured in rats.
51              A second probe, (99m)Tc-labeled Duramycin, which binds to apoptotic cells, was used to m
52                            HYNIC-derivatized duramycin with 1:1 stoicheometry was synthesized and con
53 ve power of cell death imaging using (99m)Tc-duramycin with the current gold standard (18)F-FDG for t